Contrasting bioAffinity Technologies (NASDAQ:BIAF) and Protalex (OTCMKTS:PRTX)

Protalex (OTCMKTS:PRTX) and bioAffinity Technologies (NASDAQ:BIAF) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, valuation, dividends, profitability, analyst recommendations and institutional ownership.

Earnings and Valuation

This table compares Protalex and bioAffinity Technologies”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protalex	N/A	N/A	N/A	N/A	N/A
bioAffinity Technologies	$7.32 million	3.04	-$7.94 million	($0.93)	-2.05

Protalex has higher earnings, but lower revenue than bioAffinity Technologies.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Protalex and bioAffinity Technologies, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protalex	0	0	0	0	N/A
bioAffinity Technologies	0	0	1	0	3.00

bioAffinity Technologies has a consensus price target of $6.00, indicating a potential upside of 214.14%. Given bioAffinity Technologies’ higher possible upside, analysts plainly believe bioAffinity Technologies is more favorable than Protalex.

Profitability

This table compares Protalex and bioAffinity Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Protalex	N/A	N/A	N/A
bioAffinity Technologies	-120.76%	-172.06%	-106.72%

Institutional & Insider Ownership

1.6% of bioAffinity Technologies shares are owned by institutional investors. 80.0% of Protalex shares are owned by insiders. Comparatively, 36.4% of bioAffinity Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

About Protalex

Protalex, Inc. focuses on the development of biopharmaceutical drugs for treating autoimmune and inflammatory diseases in the United States. The company targets a range of autoimmune diseases, such as rheumatoid arthritis (RA), immune thrombocytopenia (ITP), psoriasis, myasthenia gravis, chronic idiopathic demyelinating polyneuropathy, and pemphigus. Its lead product candidate is PRTX-100, an immunomodulatory therapy, a highly-purified form of staphylococcal protein A, which is in Phase I/II open-label, dose-escalating study for the treatment of patients with persistent/chronic ITP; and Phase 1b clinical trial for the treatment of RA on methotrexate or leflunomide. The company was founded in 1999 and is based in Florham Park, New Jersey.

About bioAffinity Technologies

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.